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Abstract
Background: An accumulating body of evidence is consistent with the hypothesis that excessive
or prolonged increases in proinflammatory cytokine production by activated glia is a contributor
to the progression of pathophysiology that is causally linked to synaptic dysfunction and
hippocampal behavior deficits in neurodegenerative diseases such as Alzheimer's disease (AD). This
raises the opportunity for the development of new classes of potentially disease-modifying
therapeutics. A logical candidate CNS target is p38α MAPK, a well-established drug discovery
molecular target for altering proinflammatory cytokine cascades in peripheral tissue disorders.
Activated p38 MAPK is seen in human AD brain tissue and in AD-relevant animal models, and cell
culture studies strongly implicate p38 MAPK in the increased production of proinflammatory
cytokines by glia activated with human amyloid-beta (Aβ) and other disease-relevant stressors.
However, the vast majority of small molecule drugs do not have sufficient penetrance of the blood-
brain barrier to allow their use as in vivo research tools or as therapeutics for neurodegenerative
disorders. The goal of this study was to test the hypothesis that brain p38α MAPK is a potential in
vivo  target for orally bioavailable, small molecules capable of suppressing excessive cytokine
production by activated glia back towards homeostasis, allowing an improvement in neurologic
outcomes.
Methods: A novel synthetic small molecule based on a molecular scaffold used previously was
designed, synthesized, and subjected to analyses to demonstrate its potential in vivo bioavailability,
metabolic stability, safety and brain uptake. Testing for in vivo efficacy used an AD-relevant mouse
model.
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Results: A novel, CNS-penetrant, non-toxic, orally bioavailable, small molecule inhibitor of p38α
MAPK (MW01-2-069A-SRM) was developed. Oral administration of the compound at a low dose
(2.5 mg/kg) resulted in attenuation of excessive proinflammatory cytokine production in the
hippocampus back towards normal in the animal model. Animals with attenuated cytokine
production had reductions in synaptic dysfunction and hippocampus-dependent behavioral deficits.
Conclusion: The p38α MAPK pathway is quantitatively important in the Aβ-induced production
of proinflammatory cytokines in hippocampus, and brain p38α MAPK is a viable molecular target
for future development of potential disease-modifying therapeutics in AD and related
neurodegenerative disorders.
Background
Up-regulation of proinflammatory cytokine production
by activated glia has been implicated in disease progres-
sion in a variety of chronic neurodegenerative disorders,
including Alzheimer's disease (AD), Parkinson's disease,
multiple sclerosis, amyotrophic lateral sclerosis, and HIV-
associated dementia [for selected reviews, see [1-10]]. In
AD, studies with clinical samples and investigations using
animal models provided strong correlations of early
increases in proinflammatory cytokine levels, especially
interleukin-1β (IL-1β) and tumor necrosis factor α
(TNFα), prior to neurologic sequelae [5,11,12]. Causal
relationships were established by demonstration of a
worsening of neuropathologic outcomes as a result of
experimentally manipulated increases in proinflamma-
tory cytokines or an improvement of outcomes with treat-
ments that decrease cytokine levels. The former includes
the use of transgenic and knockout mouse models sub-
jected to AD-relevant stress [13,14], or direct administra-
tion of cytokines to the brain [15-19]. The latter includes
treatment with small molecules that suppress excessive
cytokine production by glia back towards basal [20-23].
This accumulating body of evidence is the foundation of
current efforts to decipher which combinations of disease-
relevant stressors and signal transduction pathways might
be amenable to therapeutic interventions that modulate
cytokine production [for review, see [1]].
Current drugs approved for human use to modulate
cytokine function are macromolecules [e.g., see [24,25]].
Although a clinical feasibility study in AD patients raises
the potential of positive neurologic outcomes [26], mac-
romolecular drugs have a number of disadvantages for
clinical use in chronic CNS disorders, including high cost
and inconvenient dosing regimens. Thus, there is a critical
need for orally active, brain-penetrant, small molecule
therapeutics that can suppress excessive proinflammatory
cytokine production by glia back towards homeostasis
without being pan-suppressors, such as steroids with their
untoward side effects and poor ability to alter pathophys-
iology progression [27,28].
Recently, we developed an experimental therapeutic
whose mechanism of action is reduction of excessive
proinflammatory cytokine levels in the hippocampus
back towards basal levels, with a resultant attenuation of
synaptic dysfunction and hippocampus-dependent
behavior alteration [22,23,29]. The drug, Minozac, is in
clinical development. Minozac discovery and develop-
ment used a de novo compound discovery platform inter-
faced with hierarchal biological screens for oral
bioavailability, toxicity, brain penetrance, and stability.
Compounds emerging from the platform were tested for
efficacy in animal models of CNS disorders [22,23,30],
employing the more unbiased functional approach to
drug discovery that has proven attractive for complex dis-
orders and initial therapy development in areas of unmet
need [31,32]. Minozac, therefore, provides a precedent for
selective targeting of increased proinflammatory produc-
tion with positive neurologic outcomes in an AD-related
neurodegenerative disease model. Minozac is not an
inhibitor of p38α MAPK, an established drug discovery
target for peripheral tissue diseases, such as rheumatoid
arthritis, that are also characterized by increased proin-
flammatory cytokine production as part of disease pro-
gression [for reviews, see [33-38]]. In contrast to the
extensive knowledgebase for peripheral tissue disorders,
less is known about the in vivo contributions of the p38α
MAPK signaling cascade to the brain cytokine overproduc-
tion and neurodegenerative sequelae in CNS disorders
such as AD, or the potential of p38α MAPK as a therapeu-
tic target for such disorders [for reviews, see [39,40]].
The p38 MAPK signaling cascade is activated in AD as
demonstrated by staining of AD brain tissue samples for
phosphorylated (activated) p38 MAPK or upstream com-
ponents of the pathway [19,41-46]. Activation of the p38
MAPK pathway is also seen in AD-relevant animal models
[47-51]. However, causative linkages between MAPK
pathway activation and proinflammatory cytokine pro-
duction by glia is mainly via cell culture studies. For exam-
ple, stimulation of glial cell cultures with Aβ1–42 induces
p38 MAPK activation [52-56] with a later induction of
proinflammatory cytokines, and p38 MAPK inhibitors
block the increase [see, e.g., [53,56-58]]. Therefore, thereJournal of Neuroinflammation 2007, 4:21 http://www.jneuroinflammation.com/content/4/1/21
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is a body of strongly suggestive evidence that brain p38α
MAPK may be a viable therapeutic target for AD and
related neurodegenerative disorders. Further pursuit of
this hypothesis requires the use of brain-penetrant, small
molecule p38α MAPK inhibitors to demonstrate restora-
tion of Aβ-induced up-regulation of brain cytokine pro-
duction back towards normal, with an associated
improvement in neurologic outcomes.
In order to fill this void in knowledge and provide a foun-
dation for future therapeutic development efforts, we
employed the same chemical scaffold used for Minozac
development to design and produce a novel p38α MAPK
inhibitor with potential for use in studies of brain pathol-
ogy alteration in AD-relevant animal models. The ration-
ale for using chemical diversification of the Minozac
scaffold is two-fold. First, analog design is one of the most
successful for the development of novel small molecule
drugs, with approximately two-thirds of all small mole-
cule sales resulting from the analog approach [59]. Sec-
ond, greater than 98% of small molecule drugs have
inadequate blood-brain barrier penetrance [60]. Minozac
[22] and the lead compound from which it was devel-
oped, MW01-5-188WH [23], use a common scaffold and
have good blood-brain barrier penetrance, justifying
redundant use of this scaffold in attempts to discover a
p38α MAPK targeted inhibitor for altering CNS patho-
physiology.
We describe here the development of a novel, orally bioa-
vailable, brain-penetrant, non-toxic p38α MAPK inhibitor
and its in vivo use at a low oral dose to attenuate human
Aβ-induced increases in mouse hippocampus cytokine
levels, consistent with the proposed mechanism of inhib-
itor action. Improved neurologic endpoints support the
hypothesis that p38α MAPK is a viable target for future
drug development.
Methods
Design and synthesis of MW01-2-069A-SRM
Compound MW01-2-069A-SRM (hereafter designated
069A) was designed based on the inactive core 3-phenyl-
6-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine scaffold,
which was also used in the fragment-based discovery of
MW01-5-188WH and Minozac [22,23]. The scaffold was
subjected to chemical diversification by introduction of
the 4-pyridinyl pharmacophore as shown in Fig. 1. Phar-
macophore modeling was assisted by the use of the p38α
MAPK crystal structure 1YQJ in the Protein Database and
the commercially available software FlexX-pharm (Tripos,
Inc., St. Louis, MO). Structure-based searches of the liter-
ature to demonstrate novelty of the 069A chemical struc-
ture were done with SciFinder Scholar®  (American
Chemical Society).
The synthetic scheme for the production of 069A is shown
in Fig. 1. The synthesis of 069A was accomplished by the
generation of a precursor, compound 5, that was amena-
ble to introduction of the pyridinyl functionality by stand-
ard cross-coupling chemistry and using commercially
available reagents and catalysts (Scheme 1, step e). The
generation of the precursor compound 5 required a varia-
tion of the previously described [22,23,29] generalized
synthetic scheme. This was accomplished by first (step c)
introducing the amine 4-(pyrimidin-2-yl)piperazine onto
the pyridazine ring to generate compound 4, followed by
a halogenation reaction to make the reactive precursor
compound 5.
Details corresponding to each step in the synthetic
scheme are described below. The starting material, rea-
gents and solvents used in this synthetic scheme are com-
mercially available, or readily generated from
commercially available materials using standard chemical
reactions. The detailed reaction conditions presented for
each step represent specific variations of established
chemical reactions previously described in the literature,
but brought together in a new single scheme to produce
the desired novel product in good yield and with no
major safety concerns. This scheme allows a qualified
Synthetic scheme for synthesis of MW01-2-069A-SRM Figure 1
Synthetic scheme for synthesis of MW01-2-069A-
SRM. Reactions, conditions and yields: a) POCl3, reflux, 2 
hrs, 99%; b) NaOH, H2O, reflux, 2 hrs, 67%; c) 1-(2-pyrimi-
dyl)piperazine, 1-butanol, 130°C, 26 hrs, 98%; d) POCl3, 
reflux, 3 hrs, 99%; e) 4-pyridylboronic acid, Pd(PPh3)4, 
K2CO3, DME, 110°C, 15 hrs, 74%.
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investigator or contract laboratory to produce the inhibi-
tor with standard laboratory facilities.
All intermediates were confirmed by HPLC and mass
spectrometry (MS). The structure and purity of the final
compound were confirmed by HPLC, MS and 1H-NMR. A
Dionex HPLC system (Dionex, Sunnyvale, CA) equipped
with a Dionex P680 pump and UVD170U ultraviolet
detector was used for analytical and bioanalytical analyses
of tissue extracts, equipped with a Phenomenex (Tor-
rance, CA) Luna C18 column (250 × 2.0 mm; 5 µm) and
guard column with a flow rate of 0.2 mL/min. The mobile
phase consisted of 0.1 % (v/v) formic acid (HPLC grade;
Fluka/Sigma-Aldrich, St. Louis, MO) in HPLC grade water
as reagent A and either 100% acetonitrile (HPLC grade;
Burdick & Jackson, Morristown, NJ) or 80% acetonitrile/
0.08% formic acid/water as reagent B. UV absorption was
monitored at four wavelengths (215, 230, 260 and 300
nm) with the 260 nm trace being the standard one used
for quantification.
Compound 1: 5-bromo-6-phenylpyridazin-3(2H)-one
The starting material compound 1 was obtained from GL
Synthesis Inc. (Worcester, MA) and manufactured in two
steps using Friedel-Crafts alkylation of benzene with
mucobromic acid to make 2,3-dibromo-4-phenylcrot-
onolactone, which upon treatment with hydrazine yields
5-bromo-6-phenylpyridazin-3(2H)-one 1 [61-63].
Compound 2: 4,6-dichloro-3-phenylpyridazine
Chlorination of compound 1 with phosphorus oxychlo-
ride (10 eq, > 99%) yielded 4,6-dichloro-3-phenylpyri-
dazine, or compound 2. The reaction was done under
reflux (90°C) for 2 hrs, with 5 M NaOH solution used to
control the HCl formed during the course of reaction.
After completion, the reaction mixture was cooled to
ambient temperature and poured onto crushed ice. The
mixture was neutralized with a 5 M NaOH solution to give
a white suspension. The suspension was filtered on a
medium frit sintered glass funnel to collect the solid. The
filter cake was washed three times with deionized water
and air dried on the filter to provide the compound 2 in
99% gravimetric yields. ESI m/z (MeOH): 225.4 (MH+).
Compound 3: 6-chloro-3-phenylpyridazin-4-ol
Compound 2 and NaOH (1.85 eq,) were suspended in
deionized water and heated under reflux (130°C) until a
clear solution formed (~2 hrs). The reaction mixture was
cooled in an ice water bath and acidified with HCl to pH
= 1. The forming solid was filtered on medium frit sin-
tered glass funnel and washed with 2 M Na2CO3 solution.
The collected filtrate was again acidified with 2 M HCl to
pH = 1, generating a white solid, which was collected by
filtration on a medium frit sintered glass funnel, washed
with deionized water and taken to dryness on the filter.
The solid obtained was the desired product 3  in 67%
gravimetric yield. ESI m/z (MeOH): 207.03 (MH+).
Compound 4: 3-phenyl-6-(4-(pyrimidin-2-yl)piperazin-1-
yl)pyridazin-4-ol
Compound 3 and 1-butanol were placed in a heavy wall
pressure vessel (Chemglass, Vineland, NJ) and 1-(2-
pyrimidyl)piperazine (4 eq) was added. The pressure ves-
sel was closed and heated at 130°C for 26 hrs. The reac-
tion mixture was cooled to ambient temperature,
transferred to a round bottom flask and concentrated in
vacuo. The residue was treated with deionized water and
the precipitate was collected by filtration on a medium frit
sintered glass funnel, the filter cake washed three times
with deionized water, and dried over a filter funnel in
vacuo to give the desired product 4 in 98% gravimetric
yield. ESI m/z (MeOH): 335.2 (MH+).
Compound 5: 4-chloro-3-phenyl-6-(4-(pyrimidin-2-
yl)piperazin-1-yl)pyridazine
Compound 4 was suspended in phosphorus oxychloride
(ReagentPlus Grade, > 99%). The reaction mixture was
heated under reflux (90°C) for 2 hrs, cooled to ambient
temperature and poured onto crushed ice. The mixture
was neutralized with 5 M NaOH solution to give a white
suspension. The precipitate was collected by filtration on
a medium frit sintered glass funnel, the filter cake was
washed with deionized water and dried in vacuo to give
the product 5 in 99% gravimetric yield. ESI m/z (MeOH):
353.3 (MH+).
Compound 6 (MW01-2-069A-SRM): 3-phenyl-4-(pyridin-
4-yl)-6-(4-pyrimidin-2-yl)piperazin-1-yl)pyridazine
Compound  5  and pyridin-4-yl boronic acid (1.35 eq,
Sigma-Aldrich, St. Louis, MO) were suspended in dimeth-
oxyethane and water in a heavy wall pressure vessel
(Chemglass, Vineland, NJ). The reaction mixture was
purged with argon for 10 min. Tetrakis(triphenylphos-
phine)palladium (0.07eq, STREM Chemicals, Newbury-
port, MA) and sodium carbonate (3 eq) were added and
the reaction mixture was heated at 110°C for 15 hrs. The
reaction mixture was cooled to ambient temperature and
filtered though a medium frit sintered glass funnel filled
with Celite® 545. The filtrate was concentrated in vacuo,
dissolved in ethyl acetate and washed with deionized
water. The organic layer was dried with sodium sulfate,
concentrated in vacuo, triturated with hexanes, and recrys-
tallized from ethanol. The final product was obtained as
light yellow crystals in 74% gravimetric yield. The final
purity of the inhibitor was examined by reverse phase
HPLC (> 99%) and the structure was confirmed by mass
spectrometry (ESI) and 1H-NMR. ESI m/z (MeOH): 396.3
(MH+).1H-NMR (CDCl3): 8.57 (d, J = 5.7 Hz, 2H); 8.35
(d, J = 4.7 Hz, 2H); 7.34 (d, J = 6.7 Hz, 2H); 7.25 – 7.32
(m, 3H); 7.14 (d, J = 5.7 Hz, 2H); 6.89 (s, 1H); 6.56 (t, JJournal of Neuroinflammation 2007, 4:21 http://www.jneuroinflammation.com/content/4/1/21
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= 4.7 Hz, 1H); 4.03 (t, J = 4.7 Hz, 4H); 3.87 (t, J = 4.7 Hz,
4H). HPLC (tr/purity): 18.97 min/> 99%. Melting point:
221.3 – 221.5°C.
Synthesis of MW01-4-119SRM, m-pyridinyl analog of 
compound MW01-2-069A-SRM: 3-phenyl-4-(pyridin-3-yl)-
6-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine
Compound  5  and pyridin-3-yl boronic acid (1.37 eq,
Sigma-Aldrich, St. Louis, MO) were suspended in diox-
ane/water (4 mL/1 mL) in a 10 mL microwave glass vessel.
The reaction mixture was purged with argon for 5 min.
Tetrakis(triphenylphosphine)palladium (0.1eq, STREM
Chemicals, Newburyport, MA) and sodium carbonate (3
eq) added. Microwave irradiation of 30 W was used, the
temperature being ramped from ambient to 150°C. Once
the set temperature of 150°C was reached, it was main-
tained for 20 min. The reaction was allowed to cool to
ambient temperature, ethyl acetate added, and the reac-
tion mixture filtered through a medium frit sintered glass
funnel filled with Celite® 545 and dried over MgSO4. The
solvent was removed and the residue was triturated sev-
eral times with hexanes. Recrystallization from ethylace-
tate afforded the desired product in 64% gravimetric yield.
The compound purity was examined by reverse phase
HPLC and confirmed by mass spectrometry (ESI). ESI m/
z (MeOH): 396.53 (MH+). HPLC (tr/purity): 19.99 min/>
98%.
Synthesis of other compounds
Minozac, MW01-3-183WH, and MW01-6-189WH were
synthesized, purified, and characterized as previously
described [22].
Aqueous solubility determination (log S)
For aqueous solubility (log S) determination, compound
069A was weighed on a Sartorius AG (Goettingen, Ger-
many) analytical balance, and Milli-Q water was added to
create an oversaturated solution (suspension). Sample
tubes were stirred for 24 hrs at ambient temperature (t =
22°C). 1 mL of the samples were centrifuged in a micro-
fuge at 16,000 × g for 10 min, and 20 µL was subjected to
reverse-phase HPLC analysis to determine the concentra-
tion of the compound (caq). The concentration of com-
pound in the aqueous phase (caq) was determined by peak
detection at 254 nm at the appropriate retention time rel-
ative to a standard curve obtained from serial dilutions of
the compound. The log S was calculated as common log-
arithm (log10) of caq.
Lipophilicity determination (log P)
The partition coefficient was determined by the shake-
flask method [64-67]. The starting solution (0.3 mg/mL)
of analyzed compound was prepared in presaturated 1-
octanol (Sigma-Aldrich, St. Louis, MO). 1 mL of the octa-
nol phase was agitated on a plate shaker with 10 mL of
presaturated Milli-Q water for 2 hrs at 25°C. After parti-
tioning, 1 mL of the aqueous phase was centrifuged in a
microfuge for 10 min at 16,000 × g. 20 µL of the sample
were analyzed with reversed-phase HPLC as described
above to determine the concentration of the aqueous
phase (caq). The log P is calculated according to the for-
mula: log P = log10 [(0.3 – caq)/caq].
Protein kinase inhibitor activity
Concentration-dependent inhibition of protein kinase
activity was done essentially as previously described [68].
Active p38α/SAPK2α enzyme was obtained from Milli-
pore (Billerica, MA), and bovine myelin basic protein sub-
strate was obtained from Sigma-Aldrich (St. Louis, MO).
Enzyme activity assays were done in a final volume of 50
µl and each point was tested in duplicate. Assays were
done by incubation with 0.33 mg/ml (18 µM) myelin
basic protein, 100 µM ATP and γ-[32P]ATP (specific activ-
ity > 300 cpm/pmol) in assay buffer (50 mM HEPES, pH
7.5, 5 mM MgCl2, 150 mM KCl, 15 mM NaCl, 1 mM
DTT). Reactions were initiated by addition of the active
p38α kinase at a final concentration of 2 µg/ml, and incu-
bated for 10 min at 30°C. Reactions were stopped by
transfer of a 35 µl aliquot of the assay mixture onto P81
paper (Whatman, Clifton, NJ), washes with 75 mM phos-
phoric acid and 95% ethanol, and quantification by scin-
tillation counting. When compounds were tested for
kinase inhibitory activity, 10X stock solutions of com-
pounds were prepared in DMSO or water, and control
samples contained the same final concentration of solvent
as the samples containing compound. Data are expressed
as percent of the maximal enzyme activity, where enzyme
activity in the absence of compound is taken as 100%.
IC50 values were calculated by a nonlinear regression data
analysis using Microsoft Excel. Selectivity against pathway
or structurally related protein kinases was done using
purified kinases and standard in vitro assays described pre-
viously [69,70], and included use of the Millipore (Biller-
ica, MA) kinase screening service at 20 µM final
concentration of 069A and 90 µM final concentration of
ATP.
Oral bioavailability and brain uptake analysis
Analysis of oral bioavailability (concentration of com-
pound in the blood as a function of time after oral admin-
istration) and brain uptake was done by a modification of
that previously described [22]. Briefly, 069A (2.5 mg/kg)
was administered to C57Bl/6 mice by oral gavage in a
0.5% (w/v) carboxymethylcellulose suspension. At 5, 15,
30, 60, and 120 min after compound administration,
blood was collected in heparinized tubes from anesthe-
tized animals and plasma obtained by centrifugation.
After perfusion, brains were harvested, homogenized in
0.1% formic acid and deproteinized with ice-cold ace-
tonitrile. After centrifugation to remove precipitated pro-Journal of Neuroinflammation 2007, 4:21 http://www.jneuroinflammation.com/content/4/1/21
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tein, the brain homogenate supernatants were further
diluted with 0.1% formic acid. The plasma samples were
acidified by diluting with 0.1% formic acid (1:3, v:v).
Solid phase extraction followed by HPLC analysis was
used to quantify the amount of compound in the plasma
and brain supernatants, with compound MW01-6-
189WH used as an internal standard. Briefly, 30 mg car-
tridges (Oasis® HLB, Waters) were conditioned with 1 mL
of acetonitrile and equilibrated with 1 mL of water. Acid-
ified samples were loaded onto the cartridge followed by
a 1 mL wash with 5% acetonitrile. Compound was eluted
from the cartridge using 100% acetonitrile. The eluate was
evaporated to dryness, reconstituted in 60% acetonitrile/
0.1% formic acid/water and analyzed by HPLC. Recovery
of internal standard and compound 069a was approxi-
mately 70%.
Liver toxicity screen
Screening for histological liver injury after chronic, thera-
peutic dose administration of compound was done as pre-
viously described [22,23]. Briefly, C57Bl/6 mice were
administered by oral gavage either 069A (2.5 mg/kg) or
solvent control (DMSO) in a 0.5% (w/v) carboxymethyl-
cellulose suspension. Compound or vehicle administra-
tion was once daily for two weeks. Livers were then
removed, fixed in 4% (v/v) paraformaldehyde, and paraf-
fin-embedded for histology. To assess histological toxic-
ity, 4 µm liver sections were stained with haematoxylin
and eosin. Two independent observers blinded to the
treatment groups performed microscopic assessment of
the tissue for injury by using a semi-quantitative histolog-
ical scoring system that considers architecture features
(normal to extensive fibrosis), cellular features (normal to
extensive edema and widespread necrosis), and degree of
inflammatory infiltrate (normal to extensive infiltrate).
Stability in human liver microsomes
Analysis of metabolic stability of compound 069A, Min-
aprine (Sigma-Aldrich), and Minozac [22] was tested in
vitro by using commercially available human liver micro-
somes and an NADPH-regenerating system (BD Bio-
sciences Discovery Labware; Woburn, MA), by the
method previously described [71]. Briefly, triplicate reac-
tion mixtures contained 0.1 M potassium phosphate
buffer (pH 7.4) and a final concentration of the following
components: 1 – 1.6 mg/ml total microsomal protein, 5
µM test compound, 1.3 mM NADPH, 3.3 mM MgCl2, 0.4
U/ml glucose-6-phosphate dehydrogenase, and 3.3 mM
glucose-6-phosphate in a total volume of 300 µl. Mixtures
were incubated at 37°C for 10 or 30 minutes. Reactions
were terminated by addition of ice cold acetonitrile, cen-
trifuged at 12,000 × g for 10 min to pellet precipitated
microsomal protein, and the supernatant analyzed by
HPLC to quantify the percentage of the initial amount of
parent compound remaining after incubation. HPLC was
performed as described above with 0.1% (v/v) formic acid
in water as reagent A and acetonitrile with 0.1% (v/v) for-
mic acid in water as reagent B. Peak quantification was
done based upon absorption measurements at 260 nm
relative to a standard curve obtained by serial dilutions of
compounds. Control incubations revealed loss of com-
pounds due to microsomal binding was less than 10%.
In vivo efficacy in AD mouse model
The four-week intracerebroventricular (ICV) infusion of
human oligomeric Aβ1–42  or Hepes/HDL vehicle into
C57Bl/6 mice was done as previously described [22,23].
Mice were administered by oral gavage either 069A (2.5
mg/kg) or solvent control (DMSO) in a 0.5% (w/v) car-
boxymethylcellulose suspension. Compound administra-
tion began at day 21 after the start of Aβ infusion, and
continued on a once daily administration schedule for 14
days. Beginning at day 50 after the start of Aβ infusion, the
Y-maze test of spontaneous alternation was done once
daily for 10 days to evaluate hippocampal-dependent spa-
tial learning as described previously [23]. At day 60, mice
were anesthetized, perfused, and sacrificed as previously
described [23]. Hippocampal extract supernatants were
prepared by dounce and sonication, followed by centrifu-
gation as described previously [23]. Levels of the proin-
flammatory cytokines IL-1β and TNFα in hippocampal
supernatants were measured by ELISA (Biosource Interna-
tional) per the manufacturer's instructions. S100B and
synaptophysin levels were measured by ELISA as previ-
ously described [23].
Statistical analyses of in vivo results
Experimental and control groups were compared using
one-way ANOVA with Newman-Keuls post-hoc analysis
using GraphPad Prism, version 4.00 statistical software.
Significance was assumed when p < 0.05.
Results and Discussion
Development and characterization of a novel p38 MAPK 
inhibitor with potential use for CNS studies
The synthetic scheme (Fig. 1) and design strategy (Fig. 2)
for the p38 MAPK inhibitor 069A were based on a chem-
ical diversification of the inactive 3-phenyl-6-(4-(pyrimi-
din-2-yl)piperazin-1-yl)pyridazine scaffold (MW01-3-
183WH; Fig. 3), used in previous development of CNS-
penetrant, orally bioavailable, non-toxic, experimental
therapeutics [22,23]. Computational modeling predicted
that the scaffold should fit into the p38α MAPK structure,
with the phenyl ring occupying a hydrophobic pocket in
the kinase (Fig. 2A). To create the potential for further
interaction with the p38 MAPK active site, we introduced
into the scaffold a pyridinyl pharmacophore found in a
variety of p38 MAPK inhibitors [72-74]. The nitrogen of
the pyridine ring is potentially able to make a critical H-
bond interaction with the amide bond formed betweenJournal of Neuroinflammation 2007, 4:21 http://www.jneuroinflammation.com/content/4/1/21
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Met109 and Gly110 of p38α MAPK. Therefore, we incor-
porated this feature into the design of 069A.
The activity of 069A as a p38α MAPK inhibitor was tested
in an in vitro protein kinase assay over a wide concentra-
tion range (0.05 – 12 µM). As shown in Fig. 3A, 069A
inhibits p38α MAPK activity in a concentration-depend-
ent manner with an estimated IC50 of 0.8 µM. As shown in
Fig. 3B, the starting scaffold (compound MW01-3-
183WH) lacks inhibitory activity, consistent with the
model in Fig. 2. Therefore, introduction of the pyridinyl
pharmacophore adjacent to the phenyl ring of the inactive
scaffold to generate 069A results in a greater than 100-fold
increase in inhibitory activity.
To further validate the design approach and specificity of
the inhibitor-kinase interaction, we examined in more
detail the finding that introduction of the pyridinyl phar-
macophore into the inactive scaffold generated kinase
inhibitory activity. The attainment of p38 MAPK inhibi-
tory activity is dependent on the molecular context of the
pyridinyl pharmacophore placement. For example, we
synthesized an analog, called MW01-4-119SRM, to test
the activity importance of the potential H-bond interac-
tion with the Met109 peptide backbone of the kinase. We
used the same synthetic scheme as used for 069A, but a
different pyridinylboronic acid (Fig. 1, step e), allowing a
different structural orientation of the nitrogen in the pyri-
dine ring. If the proposed interaction (Fig. 2) involves
such an H-bond, one would anticipate that activity would
be compromised due to distance constraints and altered
electronegativity. As shown in Fig. 3B, there was a major
loss of activity back toward that seen with the scaffold
alone. The remarkable gain in activity with the introduc-
tion of the pyridinyl pharmacophore into the scaffold to
generate 069A is also dependent on the location of the
pyridine on the scaffold. For example, placement of the
pyridine ring at a different location on the pyridazine ring,
such as in compound MW01-6-189WH (Fig. 3B), does
not generate MAPK inhibitory activity (Fig. 3B). There-
fore, compounds with identical compositions to 069A,
but different structures, are not able to replicate the kinase
inhibitory activity of 069A.
Another feature of the model in Fig. 2 relates to the "gate-
keeper residue" characteristic of many protein kinases. In
p38α and p38β, the gatekeeper residue is Thr106, whereas
a larger Met residue is found in the analogous position in
Design of MW01-2-069A-SRM Figure 2
Design of MW01-2-069A-SRM. A) Pharmacophore model showing the potential for 069A to make selective interactions in 
the active site of p38α MAPK. The pyridine ring nitrogen has the potential to make the critical interaction with the hydrogen of 
the amide bond formed between Met109 and Gly110. This interaction and the potential to occupy the nearby hydrophobic 
pocket are important interactions for p38α MAPK selective inhibitors. The "gatekeeper residue" in p38α and p38β is Thr106. 
Its small size compared to the larger Met in p38δ and p38γ isoforms allows bulkier groups in the compound to access the 
pocket, thereby providing isoform selectivity and potential affinity. B) Amino acid sequence alignment of p38 MAPK isoforms 
in the region containing key amino acids implicated in selective kinase-inhibitor interactions.
N
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p38δ and p38γ (Fig. 2B). The smaller Thr residue allows
bulkier groups, such as the phenyl at position 6 of the
pyridazine ring in 069A, to access the hydrophobic pocket
found in the kinase active site. Based on structure param-
eters, therefore, we would predict that 069A should be a
selective inhibitor of p38α and p38β, but not be an inhib-
itor of the p38δ and p38γ isoforms. This selectivity was
validated as part of an in vitro protein kinase screen done
by Millipore (Billerica, MA); at 20 µM, 069A showed com-
plete inhibition of p38α enzyme activity, partial inhibi-
tion of p38β, and no inhibition of p38δ or p38γ (Table 1).
In addition, there was little or no inhibition by 069A of 44
other purified protein kinases (Table 1). Clearly, the pyri-
dine pharmacophore must be introduced adjacent to the
phenyl group in the molecular context of the scaffold, as
found in compound 069A, to generate a p38α MAPK-
selective inhibitor.
Approved drugs and experimental therapeutics that are
protein kinase inhibitors generally exhibit inhibition con-
stants ≤ 1 µM and perturb intracellular signal cascades.
This apparent affinity of efficacious kinase inhibitors is
consistent with their ability to compete with the endog-
enous substrates (ATP and physiological protein sub-
strates), for which kinases generally have Km values in the
1–20 µM range. This requires that an inhibitor have com-
parable or better affinity for the kinase than its physiolog-
ical substrates for efficacy. The affinity and selectivity of
069A for inhibition of p38 MAPK activity justified further
biological characterization of this compound. However,
in order to interpret the in vivo biological effects of such an
inhibitor, there must be some indication that the com-
pound is bioavailable, stable and non-toxic.
Molecular properties and bioavailability of the p38α 
MAPK inhibitor
Molecular properties are physical features of small mole-
cules that generally define what makes a chemical drug-
like and likely to be taken up into the bloodstream (bioa-
vailable) because they are associated with the ability to
exist in aqueous biological milieu yet able to reversibly
penetrate biological membranes. A compound's molecu-
lar properties, such as lipophilicity and aqueous solubil-
ity, also contribute to whether or not the drug is rapidly
metabolized by liver enzymes after being consumed by
mouth, and are a major determinant of whether the com-
pound is one of the approximately 2% of small molecule
drugs that have blood-brain barrier penetrance [60]. The
de novo compound discovery platform [22,23,29] used to
develop 069A uses considerations of multiple molecular
properties at both the design and synthetic compound
characterization stages. While the physical properties
associated with bioavailability and brain penetrance are
often estimated by commercially available computational
algorithms as part of compound design, they are only
approximations to assist in design and often deviate sig-
nificantly from experimentally determined values [29].
Therefore, we determined the experimental values for
lipophilicity and aqueous solubility of 069A using the
protocols described in Methods. The experimentally
determined lipophilicity of 069A yields a log P value of
3.18. This value is within the range of computed and
experimentally determined values found for orally bioa-
vailable, CNS-penetrant drugs [29]. Similarly, the experi-
mentally determined aqueous solubility of 069A is 9.54
µg/mL, which translates to a log S value of -2.02, and is a
value within the desired range [29].
The design and experimentally determined properties of
the unformulated 069A suggest its potential to be orally
Inhibition of p38α MAPK enzyme activity and validation of  design for selective interactions Figure 3
Inhibition of p38α MAPK enzyme activity and valida-
tion of design for selective interactions. A) MW01-2-
069A-SRM inhibits p38α MAPK enzyme activity in a concen-
tration-dependent manner. B) In contrast, the 069A analogs 
are > 100-fold less active. These include the starting scaffold 
(MW01-3-183WH), an analog (MW01-4-119SRM) with a dif-
ferent orientation of the pyridine ring nitrogen such that 
potential H-bond interactions are minimized, and an analog 
(MW01-6-189WH) with the pyridine ring at a different posi-
tion on the scaffold. The in vitro phosphorylation of the stand-
ard protein substrate, myelin basic protein, by purified p38α 
MAPK was measured as described in Methods, in the 
absence or presence of increasing concentrations of com-
pound. Data are expressed as percent of the maximal 
enzyme activity, where enzyme activity in the presence of 
solvent only (absence of inhibitor) is taken as 100%. Data are 
a representative example of five experiments.
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bioavailable, CNS-penetrant, stable and non-toxic based
on previous findings with this scaffold [22,23]. Experi-
mental analyses (Fig. 4) confirmed this assumption. Spe-
cifically, 069A has acceptable oral bioavailability
properties for use with in vivo studies. The compound is
readily detected in the plasma within the earliest possible
time point (5 min) analyzed after oral administration to
mice, with bulk clearance from plasma within 60 min
after oral administration (Fig. 4A). A similar pattern of
time-dependent change in concentration is seen in the
brain homogenates (Fig. 4B) prepared after perfusion of
animals to remove any compound present in adventi-
tiously associated blood. The peak brain concentration of
069A is seen at 5–15 min after oral administration, with
bulk compound clearance by 60 min. Compound 069A
did not induce any major untoward tissue injury, as
assessed by histologic screening for idiopathic liver injury.
Specifically, histological assessment of liver tissue showed
that oral administration of 069A at 2.5 mg/kg daily for 2
weeks did not induce any histological indices of liver tis-
sue injury compared with mice treated with the vehicle
(Fig. 4C), and no adverse clinical effects of 069A adminis-
tration were observed during the course of treatment.
Finally, 069A also showed acceptable metabolic stability
in human liver microsomes, with ~70% of the compound
remaining after 10 min incubation with microsomes (Fig.
4D). Although 069A is not as metabolically stable as
Minozac, it is more stable than the structurally related,
clinical CNS drug Minaprine (Fig. 4D).
These data document that 069A has lipophilicity and sol-
ubility properties that fall within the working range of val-
ues for these molecular properties in CNS drugs [29], and
that the compound is sufficiently bioavailable, metaboli-
cally stable, non-toxic, and brain-penetrant for in vivo effi-
cacy testing in CNS pathology models.
In vivo efficacy in AD animal model
The in vivo efficacy of orally administered 069A was tested
in a mouse model of AD-relevant pathophysiology that
involves ICV infusion of oligomeric Aβ1–42 [22,23]. Ani-
mal models using ICV infusion of Aβ have good pheno-
typic penetrance of pathophysiology endpoints, including
proinflammatory cytokine up-regulation, synaptic dys-
function, and hippocampal-dependent behavioral defi-
cits, and have been used to identify compounds now in
clinical trials [22,75]. The experimental design and treat-
ment paradigm are shown diagrammatically in Fig. 5. The
dose of 069A chosen to test was based on previous in vivo
success with other suppressors of proinflammatory
cytokine up-regulated production based on the same scaf-
fold [22,23].
As shown in Fig. 5, Aβ induces an increase in the levels of
the proinflammatory cytokines IL-1β, TNFα and S100B in
hippocampal extracts. Once-daily oral administration of a
low dose (2.5 mg/kg) of 069A for 2 weeks, using a trans-
lational medicine paradigm of therapy after start of injury
(21 days after the start of Aβ infusion), significantly
reduced the overproduction of IL-1β (Fig. 5A), TNFα (Fig.
5B), and S100B (Fig. 5C) back toward basal. As shown in
Fig. 6, Aβ exposure decreases the level of the presynaptic
marker protein synaptophysin in hippocampal extracts,
and induces a deficit in the Y-maze test of hippocampal-
dependent spatial behavior. Oral administration of 069A
attenuates this loss of synaptophysin (Fig. 6A) and amel-
iorates the Y-maze behavioral deficit (Fig. 6B). These
results demonstrate that an orally active, brain-penetrant,
Table 1: MW01-2-069A-SRM selectivity in standard kinase profiling screen
Kinase % kinase 
activity
Kinase % kinase 
activity
Kinase % kinase 
activity
Kinase % kinase 
activity
ASK1 107 IRAK4 112 MLK1 94 PKBβ 91
CDK1/cyclinB 94 JAK2 108 MSK1 94 PKBγ 100
CDK2/cyclinA 94 JNK1α 19 0 M S K 2 9 6 P R A K 8 6
CDK5/p25 90 Lyn 94 p70S6K 111 Pyk2 83
CK2 96 ERK1 90 p38α -2 ROCK-I 89
FAK 96 ERK2 99 p38β 30 RSK1 100
Fyn 98 MAPKAP-K2 97 p38δ 101 Syk 96
GSK3β 74 MAPKAP-K3 94 p38γ 95 TAK1 97
IKKα 95 MEK1 104 PAK2 116 TAO1 94
IKKβ 104 MKK4 117 PDK1 101 TAO2 92
IRAK1 110 MKK7β 103 PKBα 76 TBK1 95
The ability of 069A (20 µM final concentration of compound; 90 µM final concentration of ATP) to suppress the activity of purified kinases was 
determined in a Millipore/Upstate kinase profiling assay as described by the manufacturer. Kinase activity in the absence of inhibitor is taken as 
100%.Journal of Neuroinflammation 2007, 4:21 http://www.jneuroinflammation.com/content/4/1/21
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small molecule inhibitor of p38α MAPK is efficacious in
an AD-relevant animal model. Our findings indicate the
importance of this protein kinase mediated pathway in
AD-relevant overproduction of proinflammatory
cytokines and its linkage to neuroinflammation-related
neuronal dysfunction and behavioral deficits.
p38α MAPK as a potential CNS therapeutic target
Protein kinases constitute an important class of druggable
protein targets [76-78] and the multi-kinase inhibitors
Gleevec (imatinib mesylate; Novartis), Nexavar (soraf-
enib; Bayer, Onyx), and Sutent (sunitinib malate; Pfizer)
for treatment of various types of cancers are evidence of
the potential for kinases to be therapeutic targets. These
prior successes in cancer therapeutic development suggest
the still untapped potential with respect to a multitude of
other disease indications, such as CNS disorders. The
novel compound development and in vivo biology results
presented here add to an accumulating body of knowl-
edge supporting protein kinases as being potential thera-
peutic targets relevant for new CNS disease therapeutics, if
small molecules with appropriate molecular properties
and activity can be developed.
Bioavailability is required but is not sufficient to make a
chemical into a drug. In vivo efficacy also requires selective
inhibitory activity at the level of the target protein kinase.
The design of 069A exploited structural features previ-
ously identified [73] as being important for selectivity
among MAPK isozymes. The validity of these design
assumptions was confirmed by the synthesis and testing
of analogs less likely to exploit the key inhibitor-kinase
Compound 069A suppresses proinflammatory cytokine up- regulation in AD mouse model Figure 5
Compound 069A suppresses proinflammatory 
cytokine up-regulation in AD mouse model. A sche-
matic of the experimental paradigm is shown. Treatment 
with 069A resulted in significant suppression of the Aβ-
induced increase in the hippocampal levels of the proinflam-
matory cytokines IL-1β (A), TNFα (B) and S100B (C). Mice 
were infused ICV with either the diluent control (C) or the 
injurious oligomeric form of human Aβ1–42 (I) for 4 weeks. 
Starting at 3 weeks after the start of Aβ infusion, mice were 
administered by daily oral gavage either 069A (2.5 mg/kg; I + 
Cmpd) or vehicle (I + Veh) for two weeks. Spontaneous 
alternation of mice was measured for 10 days in the Y-maze, 
a hippocampus-dependent spatial learning task, beginning at 
day 50 after the start of Aβ infusion. Mice were sacrificed on 
day 60, and hippocampal extracts analyzed by ELISA. Data 
are means ± SEM of n = 5 mice per group. Significantly differ-
ent from Aβ-injured: *p < 0.05, **p < 0.01, ***p < 0.001.
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Oral bioavailability, brain uptake, safety and metabolic stabil- ity of 069A Figure 4
Oral bioavailability, brain uptake, safety and meta-
bolic stability of 069A. Compound bioavailability (A and 
B) was determined by administration of 069A (2.5 mg/kg) by 
oral gavage to C57Bl/6 mice, processing of blood and brain at 
different times after administration, and measuring com-
pound levels in plasma and brain homogenate extracts by 
HPLC as described in Methods. Compound 069A rapidly 
appears in plasma (A) and brain (B) within 5 min, and then 
slowly declines to basal levels by 60 min. Data are the mean 
± SEM from 5 mice at each time point. Lack of idiopathic tis-
sue injury (C) after chronic administration of compound was 
assessed by treating C57Bl/6 mice (5 mice per group) with 
either vehicle (Veh) or 069A (Cmpd; 2.5 mg/kg) by oral gav-
age once daily for two weeks. Histological liver injury was 
determined by a scoring system as described in Methods. 
There is no significant liver toxicity after chronic two-week 
administration of compound compared to vehicle, the same 
dose and paradigm used in efficacy testing. To screen for 
potential metabolic instability (D), compound 069A, the clini-
cal CNS drug Minaprine, or the drug Minozac were incu-
bated with human liver microsomes, and the amount of 
compound remaining was analyzed by HPLC as described in 
Methods. Significantly different from time 0 (**p < 0.01; ***p 
< 0.001).
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D. Stability in human liver microsomes in vitro
0 10 30
0
25
50
75
100
**
***
Time (min)
0 10 30
0
25
50
75
100
**
***
Time (min)
0 10 30
0
25
50
75
100
Time (min)
MW01-2-069A-SRM Minaprine Minozac
C. No liver toxicity
0
1
2
3
4
5
Veh Cmpd 0 30 60 90 120
0.1
0.3
0.5
0.7
0.9
1.1
Time (min)
0 30 60 90 120
0.1
0.3
0.5
0.7
0.9
1.1
Time (min)Journal of Neuroinflammation 2007, 4:21 http://www.jneuroinflammation.com/content/4/1/21
Page 11 of 14
(page number not for citation purposes)
interactions. Therefore, the use of the Minozac scaffold to
exploit its potential for bioavailability and brain pene-
trance, and chemical diversifications that allowed use of
interactions selective for p38α MAPK and p38β MAPK
over the other p38 MAPK isozymes, appear to be the
molecular basis of the in vivo efficacy of compound 069A
for brain dysfunctions.
The study summarized here does not unequivocally
address if the improved neurologic outcome is due solely
to the in vivo inhibition of glia p38 MAPK and proinflam-
matory cytokine production. For example, in vitro co-cul-
ture studies have shown [79] that inhibition of neuronal
p38 MAPK prevented decreases in synaptophysin levels
correlated with neuronal tau phosphorylation. Therefore,
it is possible that inhibition of neuronal p38 MAPK activ-
ity by 069A may have contributed to some of the in vivo
synaptic changes seen in the animal model studies
reported here. However, this is not a major concern for
therapeutic development, as the individual effects on glia
proinflammatory cytokine production and neuronal sign-
aling would both contribute to the overall positive neuro-
logic effects observed. In fact, such multi-functional
effects in the CNS due to p38α MAPK inhibition in differ-
ent cell types might be advantageous for use in a variety of
neurodegenerative disorders.
The  in vivo behavior and functional effects of 069A
allowed its use to test hypotheses in this study and the
results provide a foundation for future drug development
efforts. Targeting a protein kinase that can modulate gene
transcription and translation allows the possibility that
biological effects of the drug can continue past the time
point when the bulk drug concentration in the brain is
back to basal. In other words, the drug pharmacodynam-
ics (what the drug does to the body) could exceed its phar-
macokinetics (what the body does to the drug) with the
potential outcome being a disease-modifying therapeutic.
Clearly, these are important issues to be addressed in
future drug development investigations.
Conclusion
The studies summarized here have several important
implications. First, the data provide in vivo evidence sup-
porting the hypothesis that the gene-regulating, serine/
threonine protein kinase p38α MAPK is a potential thera-
peutic target for CNS disorders where elevated levels of
proinflammatory cytokines have been implicated as a
component of disease progression. Second, the results
presented here and previously [22,23] demonstrate that
distinct signal transduction cascades can be modulated by
small molecules to achieve the same in vivo outcome,
attenuation of up-regulated brain proinflammatory
cytokine production with resultant improvement in neu-
ropathology. Third, the methods and approach described
here demonstrate that novel tools for in vivo CNS research
can be readily developed by rational variations of existing
drug scaffolds to produce analog molecules with the
desired in vivo properties. The novel p38α MAPK inhibitor
069A provides not only an important research tool for
addressing hypotheses about the role of p38 MAPK in a
variety of CNS disorders, but also represents a potential
foundation for future campaigns to develop neurodegen-
erative disease-modifying therapies focused on this key
gene-regulating protein kinase.
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